Xcout Intel
Kadimastem competitors & alternatives
The 12 closest competitors and alternatives to Kadimastem among biotechnology companies — ranked by similarity to what Kadimastem actually does, not by market-cap band.
Subscribe to see Kadimastem’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Kadimastem
Kadimastem Ltd. is a clinical-stage cell therapy company headquartered in Ness Ziona, Israel, focused on developing advanced cell-based therapeutic treatments.
Kadimastem at a glance
Kadimastem is a biotechnology company headquartered in Israel, founded in 2008. Its most recent funding round, Debt, raised $5M in October 2021. Xcout tracks 1 named person at Kadimastem, including Michel Revel (Professor).
Kadimastem leadership
- Michel RevelProfessor
Kadimastem funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $5M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Kadimastem competitors
Ranked by semantic similarity — how close each company is to Kadimastem by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Gamida Cell is an Israeli biotechnology company developing and commercializing stem-cell and cell therapies for patients with blood cancers and other serious hematologic disorders. Its product Omisirge (omidubicel-onlv), derived from cord blood, was approved in the United States to accelerate hematopoietic stem-cell recovery after transplantation in eligible patients with blood cancers.
Similar biotechnology company
Kang Stem Biotech Co., Ltd. is a South Korean biotechnology company located in Seoul that specializes in stem cell research and development.
Similar biotechnology company
Cynata Therapeutics is a biotechnology research company headquartered in Cremorne, Australia, focused on therapeutic products and stem cell technology.
Biotech
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Similar biotechnology company
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
Biotech
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Biotech
GC Cell is a public company headquartered in Yongin-si, Gyeonggi-do, South Korea. The company is at the forefront of cell therapy innovation, with fully-integrated capabilities from research to commercialization.
Similar biotechnology company
Kodikaz Therapeutic Solutions, Inc. is a privately held biotechnology company founded in 2018 and headquartered in New York, focused on delivering advanced therapeutics.
Similar biotechnology company
Novadip Biosciences is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Belgium, focusing on innovative tissue regeneration and biopharmaceuticals.
Similar biotechnology company
BlueRock Therapeutics is a clinical-stage cell therapy company headquartered in Cambridge, Massachusetts, focused on developing engineered cellular medicines for degenerative conditions.
Similar biotechnology company
BreStem Therapeutics, Inc. is a clinical-stage biotechnology company located in Raleigh, North Carolina, focused on developing novel therapeutics to fight various diseases.
Biotech
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Kadimastem and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Kadimastemand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →